Chloroquine retinopathy

Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's weight loss doctor NYC
Philadelphia GLP-1 weight loss and GLP-1 clinic NYC
| Chloroquine retinopathy | |
|---|---|
| |
| Synonyms | Bull's-eye maculopathy |
| Pronounce | N/A |
| Specialty | N/A |
| Symptoms | Visual impairment, color vision changes, night blindness |
| Complications | Permanent vision loss |
| Onset | Typically after long-term use of chloroquine or hydroxychloroquine |
| Duration | Progressive |
| Types | N/A |
| Causes | Accumulation of chloroquine in the retina |
| Risks | High cumulative dose, long duration of use, pre-existing retinal disease |
| Diagnosis | Ophthalmic examination, visual field test, optical coherence tomography (OCT), fundus autofluorescence |
| Differential diagnosis | Age-related macular degeneration, Stargardt disease, cone dystrophy |
| Prevention | Regular eye examinations, dose adjustment |
| Treatment | Discontinuation of chloroquine or hydroxychloroquine |
| Medication | N/A |
| Prognosis | Variable; early detection can prevent progression |
| Frequency | Rare |
| Deaths | N/A |
A condition caused by the use of chloroquine, affecting the retina of the eye
Chloroquine retinopathy, also known as hydroxychloroquine retinopathy, is a retinal disorder caused by the use of the antimalarial drugs chloroquine and hydroxychloroquine. These medications are commonly used in the treatment of rheumatoid arthritis, systemic lupus erythematosus, and other autoimmune diseases. The condition is characterized by damage to the retina, particularly the macula, which can lead to vision loss if not detected early.
Pathophysiology[edit]
Chloroquine and hydroxychloroquine are known to bind to melanin in the retinal pigment epithelium (RPE), leading to toxic effects on the retina. The accumulation of these drugs in the RPE can cause damage to the photoreceptor cells and the RPE itself, resulting in the characteristic "bull's-eye" maculopathy seen in advanced cases.
Clinical features[edit]
Patients with chloroquine retinopathy may initially be asymptomatic. As the condition progresses, they may experience symptoms such as:
- Blurred vision
- Difficulty reading
- Decreased color vision
- Paracentral scotomas (blind spots)
The classic "bull's-eye" maculopathy is a late finding and indicates significant retinal damage.
Diagnosis[edit]
The diagnosis of chloroquine retinopathy is primarily clinical, supported by various imaging techniques. These include:
- Fundus photography: To document changes in the retina.
- Optical coherence tomography (OCT): To detect early structural changes in the retina.
- Visual field testing: To identify functional deficits.
- Fundus autofluorescence: To detect early RPE damage.
- Multifocal electroretinography (mfERG): To assess retinal function.
Management[edit]
The primary management strategy for chloroquine retinopathy is the early detection and cessation of the offending drug. Once significant retinal damage has occurred, it is often irreversible. Regular screening is recommended for patients on long-term chloroquine or hydroxychloroquine therapy to detect early signs of retinopathy.
Prevention[edit]
Preventive measures include:
- Baseline ophthalmologic examination before starting therapy.
- Regular follow-up examinations, typically annually, after five years of therapy or sooner if risk factors are present.
- Dose adjustment based on ideal body weight to minimize risk.
Prognosis[edit]
The prognosis of chloroquine retinopathy depends on the stage at which it is detected. Early detection and drug cessation can prevent progression and preserve vision. However, once advanced retinopathy has developed, the visual prognosis is poor.
See also[edit]
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
